EVLO

Evelo Biosciences Inc

EVLO, USA

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

https://www.evelobio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EVLO
stock
EVLO

Eliem Therapeutics (NASDAQ:ELYM) vs. Evelo Biosciences (NASDAQ:EVLO) Financial Survey Defense World

Read more β†’
EVLO
stock
EVLO

EVLO Completes Commissioning of First of Three Energy Storage Projects in American Samoa Newswire Canada

Read more β†’

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2023-09-30)

Rating:

HOLD

Target Price:

$10

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2023-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.00

Low ≀ 1

High β‰₯ 3

Return on Equity (ROE)

-

Very High

46.29 %

Low ≀ 5%

High β‰₯ 25%

Return on Assets (ROA)

-

Very Low

-59.94 %

Low ≀ 2%

High β‰₯ 10%

Investors

* Institutions hold a combined 43.64% of the total shares of Evelo Biosciences Inc

1.

Flagship Ventures Management, Inc.

(41.7884%)

since

2023/09/30

2.

Alyeska Investment Group, L.P.

(1.3965%)

since

2023/09/30

3.

Acadian Asset Management LLC

(0.2517%)

since

2023/12/31

4.

BlackRock Extended Mkt Composite

(0.1331%)

since

2023/09/30

5.

XTX Topco Ltd

(0.0537%)

since

2023/12/31

6.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0145%)

since

2023/10/31

7.

GF NASDAQ Bio-Tech Idx QDII RMB A

(0.0018%)

since

2023/12/31

8.

JHVIT Total Stock Market Index I

(0.0007%)

since

2024/01/31

9.

Daiwa Securities Group Inc

(0%)

since

2023/09/30

11.

Wells Fargo & Co

(0%)

since

2023/12/31

12.

Tower Research Capital LLC

(0%)

since

2023/12/31

13.

Northern Trust Corp

(0%)

since

2023/12/31

14.

Barclays PLC

(0%)

since

2023/12/31

15.

Millennium Management LLC

(0%)

since

2023/12/31

16.

Harbourvest Partners, LLC

(0%)

since

2023/12/31

17.

State Treasurer State Of Michigan

(0%)

since

2023/12/31

19.

Credit Suisse First Boston (CSFB)

(0%)

since

2023/12/31

20.

Alphabet Inc

(0%)

since

2023/12/31

21.

Advisor Group Holdings, Inc.

(0%)

since

2023/09/30

22.

Royal Bank of Canada

(0%)

since

2023/12/31

23.

FMR Inc

(0%)

since

2023/12/31

24.

Citigroup Inc

(0%)

since

2023/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

β€”

EPS Estimate

β€”

Latest Release

Date

2023-09-30

EPS Actual

-0.7112

EPS Estimate

-0.97

EPS Difference

0.2588

Surprise Percent

26.6804%

Investing Fit Scorecard

(Last Updated 2023-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2023-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2023-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.